Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...WPP will also reduce is planned capex from £400m to v£300m....
...And in the last two, three years, I've probably spent $10, $11 mill buying shoes. Now keep in mind, I started with $40....
...Such a transaction would continue the company’s three-year dealmaking spree, which has taken it from a run-of-the-mill generic drugmaker known as Watson Pharmaceuticals, with a market capitalisation of $8bn...
...Quarterly earnings reports are due from Accenture, General Mills, Red Hat and Rite Aid....
...General Mills (Consumer Goods) 128. Rio Tinto (Metals & Mining) 129. Walgreen Boots Alliance (Retail) 130. TripAdvisor (Online Retail) 131. American International (Insurance) 132....
...Some investors even say such a deal could pave the way for Mr Saunders to eventually replace Ian Read as chief executive of Pfizer....
...The mergers and acquisitions rumour mill has been grinding at Shire for ages. Every possible deal, one would think, has been reduced to the basic rumour particle (gosiprons?)....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Teva Pharmaceutical, the world’s biggest generic drugmaker by sales, on Thursday added its name to the rumour mill when Erez Vigodman, chief executive of the Israeli company, said he was open to “large transactions...
..., digital public services, laboratory-grown meat, augmented reality and electric-powered vehicles are just a few of the futuristic technologies elbowing their way out of the laboratory into run-of-the-mill...
...Analysts at Macquarie said the price moves in iron ore were “a classical V-shaped recovery” and reflected the fall and rise in demand....
...Industry analysts suggest that 3G Capital’s history of imposing cost cutting and greater efficiency on the companies it operates means that rivals to Heinz, such as General Mills and Kraft, will need to...
...“You have to accept it’s going to be expensive,” says Charlie Mills, analyst at Credit Suisse. “But some of the best deals around have been expensive as they are fantastic growth businesses.”...
...Less controversial is Australia, where Charlie Mills, an analyst at Credit Suisse, puts Pfizer’s market share at 51 per cent, therefore in effect out of bounds for any company in the market....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...I have to end the post on the epic basketball game played between Kellogg & Chicago Booth prior to the Chicago Bulls V Milwaukee Bucks NBA match at the United Center....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...General Mills, which makes Cheerios, reported better profits than expected, lifted by lower commodities prices and strong sales of new brands....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...Schering-Plough – it was only a matter of time before the rumour mill started to whirl into action....
International Edition